Nuclear Cardiology in the Management of Patients with Heart Failure

被引：1

作者：

Peix A. ^{[1
]}

Cabrera L.O. ^{[1
]}

Padrón K. ^{[1
]}

机构：

[1] Nuclear Medicine Department, Institute of Cardiology, 17 No. 702, Vedado, La Habana, 10 400, CP

来源：

Current Cardiovascular Imaging Reports | 2016年 / 9卷 / 1期

关键词：

Coronary artery disease; Dilated cardiomyopathy; Gated-SPECT myocardial perfusion imaging; Heart failure; Left ventricular dyssynchrony; MIBG; PET imaging;

D O I：

10.1007/s12410-015-9363-8

中图分类号：

学科分类号：

摘要：

Heart failure is increasing worldwide, resulting in considerable disability, mortality, and high healthcare costs. Gated-SPECT or PET imaging is the most prominent imaging modality useful both for diagnosis and prognosis, capable of providing information about ventricular function, presence of intraventricular synchronism, and myocardial perfusion in the same test. In addition, PET can also offer quantification of coronary blood flow and metabolism. On the other hand, 123 I- metaiodobenzylguanidine (MIBG) scintigraphy is the only imaging technique which provides information regarding the adrenergic function of the heart. This review provides an overview of the literature published over the past year relevant to this topic, presented in three parts: myocardial perfusion imaging, intraventricular synchronism assessment, and cardiac sympathetic innervation. © 2015, Springer Science+Business Media New York.

引用

页码：1 / 15

页数：14

共 76 条

[1]

Najafi F., Jamrozik K., Dobson A.J., Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure, Eur J Heart Fail, 11, pp. 472-479, (2009)

[2]

Djousse L., Driver J.A., Gaziano J.M., Relation between modifiable lifestyle factors and lifetime risk of heart failure, JAMA, 302, pp. 394-400, (2009)

[3]

Khatibzadeh S., Farzadfar F., Oliver J., Ezzati M., Moran A., Worldwide risk factors for heart failure: a systematic review and pooled analysis, Int J Cardiol, 168, pp. 1186-1194, (2013)

[4]

Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., Et al., Heart disease and stroke statistics—2013 update: a report from the American Heart Association, Circulation, 127, pp. e6-e245, (2013)

[5]

Mc Murray J.J., Adamopoulos S., Anker S.D., Auricchio A., Bohm M., Dickstein K., Et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, Eur Heart J, 33, pp. 1747-1787, (2012)

[6]

Nuclear Cardiology: guidance and recommendations for implementation in developing countries. IAEA Human Health Series No. 23 STI/PUB/1566. Vienna, Austria: IAEA, (2012)

[7]

Peix A., Mesquita C.T., Paez D., Pereira C.C., Felix R., Gutierrez C., Et al., Nuclear medicine in the management of patients with heart failure: guidance from an expert panel of the International Atomic Energy Agency (IAEA), Nucl Med Commun, 35, pp. 818-823, (2014)

[8]

Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E., Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis, J Am Coll Cardiol, 39, pp. 1151-1158, (2002)

[9]

Bonow R.O., Maurer G., Lee K.L., Holly T.A., Binkley P.F., Desvigne-Nickens P., Et al., Myocardial viability and survival in ischemic left ventricular dysfunction, N Engl J Med, 364, pp. 1617-1625, (2011)

[10]

Bax J.J., Delgado V., Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure, J Nucl Cardiol, 22, pp. 229-245, (2015)

← 1 2 3 4 5 6 7 8 →